Our Science – Dunleavy Website
Kieron M. Dunleavy, M.D.
Selected Publications |
1)
Dunleavy K, Kohler DR, Wilson WH. Non Hodgkin Lymphoma. In: Hematology-Oncology Therapy. Volume 1. New York: McGraw Hill; 2007. p. 308-346 [Book Chapter] |
2)
Healey-Bird B, Dunleavy K, White T, Wilson WH, Wiestner A. A Patient With Stage IV Mantle Cell Lymphoma Treated With Bortezomib/DA-EPOCH/Rituximab. Case Studies in Lymphoma. 5: No.2, 2007. Full Text Article. [Journal] |
3)
Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Curr. Opin. Hematol. 14: 348-53, 2007. [Journal] |
4)
Dunleavy K, Wilson WH. Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk. Lymphoma. 48: 449-51, 2007. [Journal] |
5)
Dunleavy K, Davis RE, Landgren O, Staudt LM, Wilson WH. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?. Blood. 109: 843-4; discussion 844-5, 2007. [Journal] |
6)
Dunleavy K, Staudt LM, Wilson WH. The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma. Leuk. Lymphoma. 48: 1061-3, 2007. [Journal] |
7)
Dunleavy K, Wilson W. Malignant Lymphomas. In: American College of Physicians Medicine Textbook. Volume 2. New York: WebMD; 2006. p. 2591-2608 [Book Chapter] |
8)
Dunleavy K, Kass E, Gill R, Wilson WH. Lymphomas of the Head and Neck. Emedicine. Otolaryngology and Facial Plastic Surgery. ., 2006. Full Text Article. [Journal] |
9)
Dunleavy K, Wilson WH. Primary intraocular lymphoma: current and future perspectives. Leuk. Lymphoma. 47: 1726-7, 2006. [Journal] |
10)
Dunleavy K, Wilson WH, Kaplan LD. The case for rituximab in AIDS-related lymphoma. Blood. 107: 3014-5, 2006. [Journal] |
11)
Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 106: 795-802, 2005. [Journal] |
12)
Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 105: 496-502, 2005. [Journal] |
13)
Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11: 986-91, 2005. [Journal] |
14)
Dunleavy K, Staudt L, Wilson W. Clinical Application of Molecular Profiling in Lymphomas. In: Progress in Oncology (Devita VT, Hellman S, Rosenberg S). Volume 1. Sudbury, Massachusetts: Jones and Bartlett; 2004. p. 198-220 [Book Chapter] |
15)
Nguyen JD, Dunleavy K, Carrasquillo JA, Chen CC. F-18 fluorodeoxyglucose positron emission tomographic imaging in a patient with persistent hiccups. Clinical nuclear medicine. 29: 35-6, 2004. [Journal] |
16)
Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, Leitman SF, Bolan CD. Transfusion medicine illustrated. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma. Transfusion. 44: 1679, 2004. [Journal] |
17)
McDermott RS, Maher MM, Dunleavy K, O'Keane CJ, Stack JP, Carney DP. Unusual presentations of lymphoma: Case 2. Non-Hodgkin's lymphoma presenting as liver disease. J. Clin. Oncol. 20: 1943-6, 2002. [Journal] |
This page was last updated on 1/8/2008.